Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Desmopressin (DDAVP)
Treatment for Hemophilia
Typical Dosage: 0.3 mcg/kg IV or SC, or 150-300 mcg nasally; Max 2-3 doses in 24 hours
Effectiveness
70%
Safety Score
72%
Clinical Trials
8
Participants
5K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
72
DangerousModerateSafe
Treatment Details
Dosage Range
0.3 mcg/kg IV or SC, or 150-300 mcg nasally; Max 2-3 doses in 24 hours
Time to Effect
immediate to 1 hour
Treatment Duration
acute treatment
Evidence Quality
MODERATENumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
15(Treat 15 patients to see 1 additional serious adverse event)
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,500
Monitoring:$200
Side Effect Mgmt:$300
Total Annual:$2,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
EXCELLENTICER
$10,000/QALY
QALYs Gained
0.1
Outcome-Based Costs
Cost per Responder
$2,666.67
Comparison vs Recombinant Factor VIII (for mild HA)
Cost Difference
$-300,000/year
Less expensive
QALY Difference
0.00 QALYs
Same outcomes
Dominance
DOMINATESBetter + cheaper
Prescription Access Economics
Annual Societal Loss per Patient
$1,350
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$60/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$1,500/year
Potential OTC Price
$500/year
Estimated if OTC available
Early Treatment Benefit
+0.00 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
MODERATEMissed Diagnosis Risk
LOWRequires Monitoring
YesNeeds lab work/checkups
Desmopressin (DDAVP) Outcomes
for Hemophilia
Efficacy Outcomes
Overall Effectiveness
+70%
Response Rate
+75%
Common Side Effects
Facial flushing
+35%
Headache
+20%
Hyponatremia
+8%
Dizziness
+8%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
5 completed trials for Desmopressin (DDAVP) in Hemophilia
Characterization of Laboratory Response to DDAVP in Adult Hemophilia A Carriers
NCT02506023COMPLETEDPHASE1
2 participants
INTERVENTIONAL
Atlanta, United States +1 more
Started: Jul 1, 2015
Exercise Versus DDAVP in Patients With Mild Hemophilia A
NCT03379974COMPLETEDPHASE4
32 participants
INTERVENTIONAL
Indianapolis, United States +3 more
Started: Jul 31, 2018
Efficacy and Safety of IL-11 in DDAVP Unresponsive
NCT00994929COMPLETEDPHASE2
9 participants
INTERVENTIONAL
Pittsburgh, United States
Started: Jan 1, 2010
Genetic Factors of the Desmopressin Response in Carriers of Hemophilia A
NCT06020456COMPLETED
361 participants
OBSERVATIONAL
Bordeaux, France +11 more
Started: Jan 1, 2022
Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.
NCT03054662COMPLETEDNA
142 participants
INTERVENTIONAL
Abidjan, Côte d’Ivoire
Started: Jan 16, 2017